Novartis expanded its biomedical research and drug‑development operations in India, positioning the country as a major global R&D hub for the Swiss pharmaceutical giant. Company officials said Indian teams — now numbering over 9,000 employees and representing roughly 11% of Novartis’s workforce — contribute to nearly every late‑stage molecule in the company’s pipeline. The move signals Novartis’s strategy to shift parts of innovation and data‑led discovery to India beyond traditional cost arbitrage.